Integra LifeSciences (IART) EVP granted 89,606 restricted stock units

Rhea-AI Filing Summary

Integra LifeSciences Holdings Corp reported an equity grant to executive officer Michael Damon Hutchinson, EVP, Chief Legal Officer & Secretary. On 02/02/2026, he received 89,606 restricted stock units at a price of $0 per unit, held as a direct interest.

The filing states that this restricted stock unit award will vest 100% on the second anniversary of the grant date of 02/02/2026, meaning the award is fully time‑based and contingent on continued service through that future vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hutchinson Michael Damon

Role EVP, Chief Legal Officer & Sec

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	89,606	$0.00	--

Holdings After Transaction: Restricted Stock Units — 89,606 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hutchinson Michael Damon

(Last) (First) (Middle)

1100 CAMPUS ROAD

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INTEGRA LIFESCIENCES HOLDINGS CORP [ IART ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Legal Officer & Sec

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	02/02/2026		A		89,606		(1)	(1)	Common Stock	89,606	$0	89,606	D

Explanation of Responses:

1. The award was a restricted stock unit award which will vest 100% on the second anniversary of the grant date of 02/02/2026.

Remarks:

	/s/ Lesha Shinn; Attorney-in-Fact for Michael D. Hutchinson	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did IART report for Michael Damon Hutchinson?

Integra LifeSciences (IART) reported that EVP, Chief Legal Officer & Secretary Michael Damon Hutchinson received 89,606 restricted stock units on 02/02/2026. The units were granted at a price of $0 per unit and are held as a direct ownership position.

How many restricted stock units were granted to the IART executive on 02/02/2026?

The IART executive received 89,606 restricted stock units on 02/02/2026. All 89,606 units are reported as beneficially owned after the transaction, with a transaction price of $0 per unit, reflecting a compensatory equity award rather than an open‑market purchase.

When do Michael Damon Hutchinson’s IART restricted stock units vest?

The restricted stock unit award will vest 100% on the second anniversary of the 02/02/2026 grant date. This means vesting is entirely time‑based, requiring continued service through that future vesting date before the underlying common shares are delivered.

Is the IART executive’s 89,606 restricted stock unit award a direct or indirect holding?

The 89,606 restricted stock units are reported as a direct holding. The Form 4 lists ownership form as “D” for direct, with no nature of indirect beneficial ownership disclosed, indicating the award is attributed directly to Michael Damon Hutchinson.

What role does Michael Damon Hutchinson hold at Integra LifeSciences (IART)?

Michael Damon Hutchinson serves as EVP, Chief Legal Officer & Secretary at Integra LifeSciences. His Form 4 shows this officer title and reports the grant of 89,606 restricted stock units as part of his equity-based compensation from the company.